Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford ...
On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...
The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.
The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.
The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results